Sign In
Buy OST
$1.70
+0 (+0%)
At Close: Jun 03, 2026
75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control (p = 0.003), with no new patient deaths reported since the 2-year overall survival data (75% vs.
OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World
07:20am, Friday, 29'th May 2026
The Company confirms that it will release 2.5 year overall survival data from Phase 2b clinical trial OST-HER2 in the prevention or delay of recurrence in fully-resected pulmonary metastatic osteosarc
OS Therapies Reports First Quarter 2026 Financials and Provides Business Update
06:30am, Monday, 18'th May 2026
$5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to provide Company with cash runway into 2027 $4.5 million of accrued VAT refunds
OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor
07:30am, Thursday, 14'th May 2026
Appointment strengthens medical, regulatory, and commercial leadership as Company prepares to complete early market access regulatory filings in the U.S., U.K, Europe and Australia in anticipation of
BNP Paribas Primary New Issues:POST STAB Notice - NO STAB - CLARIANE TAP
10:02am, Thursday, 30'th Apr 2026
30/04/2026 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. CLARIANE SE Post-stabilisation Period Announceme
BNP Paribas Primary New Issues:POST STAB NOTICE - NO STAB - BEFIMOO
09:42am, Thursday, 30'th Apr 2026
30/04/2026 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. BEFIMMO Post-stabilisation Period Announcement N
Conference call scheduled for Thursday, April 30, 2026, at 8:30 am ET to review new OST-HER2 immune pharmacodynamic biomarker response (seroconversion) data and review regulatory successes validating
OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET
04:01pm, Monday, 27'th Apr 2026
Regulatory feedback recent from April 2026 EU EMA and Australian TGA meetings Remaining Q2-2026 regulatory meetings include two U.S. FDA meetings and one UK MHRA meeting, in addition to follow-up meet
New York, New York--(Newsfile Corp. - April 17, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Ostin (OST) To Contact Him Directly To Discuss Their Options
NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Ostin Technology Group Co., Ltd. (NASDAQ: OST).
Bronstein, Gewirtz & Grossman LLC Urges Ostin Technology Group Co., Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Thursday, 16'th Apr 2026
New York, New York--(Newsfile Corp. - April 16, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ostin Technology Group Co., Ltd. ("Ostin" or the "Company") (NASDAQ: OST).
SUEWALLST, LLP: OST FRAUD TIMELINE REVEALS 73-DAY PATH TO $950M INVESTOR WIPEOUT
09:00am, Thursday, 16'th Apr 2026
Key Dates and Disclosure Events Shareholders Need to Know April 14, 2025: OST closes at $0.78. April 15, 2025: A $5 million registered direct offering closes, placing shares with select participants a
OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes
07:20am, Thursday, 16'th Apr 2026
New patent application covers treatment-emergent immune signature related to 'turning cold tumors hot' and the activation of targeted cytotoxic cellular immune responses Company to host conference cal
